Suppr超能文献

肝癌伴肝外转移行肝切除术的临床意义。

Clinical Significance of Hepatectomy for Hepatocellular Carcinoma Associated with Extrahepatic Metastases.

机构信息

Department of Surgery, Division of Hepato-Biliary-Pancreatic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan,

Department of Surgery, Division of Hepato-Biliary-Pancreatic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan.

出版信息

Dig Surg. 2020;37(5):411-419. doi: 10.1159/000507436. Epub 2020 May 26.

Abstract

BACKGROUND

This study evaluated the prognosis of hepatocellular carcinoma (HCC) patients with extrahepatic metastases who can undergo hepatectomy.

METHODS

A total of 32 patients who underwent hepatectomy for HCC with extrahepatic metastases, including lymph node and/or distant metastases were recruited for this study.

RESULTS

Fourteen patients had lymph node metastasis only, 16 had distant metastasis only, and 2 had both metastasis types during preoperative diagnosis. The 3-year overall survival (OS) rate of all patients was 17.9%, and the median survival time (MST) was 11.8 months. Univariate analysis revealed that intrahepatic maximal tumor size, intrahepatic tumor number, and intrahepatic tumor control after hepatectomy were significant factors influencing OS (p < 0.05). Multivariate analysis revealed that independent risk factors for OS were intrahepatic maximal tumor size and intrahepatic tumor number (p < 0.05). The MST and 3-year OS rate of patients with maximal tumor size <100 mm and intrahepatic tumor number ≤2 were 39.0 months and 51.9%, respectively.

CONCLUSIONS

Hepatectomy is not recommended for HCC patients with extrahepatic metastasis with ≥3 intrahepatic tumors, even when all intrahepatic tumors can be eliminated via hepatectomy. Aggressive surgery may be justified for HCC patients with ≤2 intrahepatic tumors and maximal tumor size <100 mm, irrespective of vascular invasion.

摘要

背景

本研究评估了可接受肝切除术的合并肝外转移的肝细胞癌(HCC)患者的预后。

方法

共纳入 32 例术前诊断为合并淋巴结和/或远处转移的 HCC 患者行肝切除术。

结果

14 例患者仅存在淋巴结转移,16 例患者仅存在远处转移,2 例患者术前诊断同时存在两种转移类型。所有患者的 3 年总生存率(OS)为 17.9%,中位生存时间(MST)为 11.8 个月。单因素分析显示,肝内最大肿瘤直径、肝内肿瘤数量和肝切除术后肝内肿瘤控制情况是影响 OS 的显著因素(p<0.05)。多因素分析显示,OS 的独立危险因素是肝内最大肿瘤直径和肝内肿瘤数量(p<0.05)。最大肿瘤直径<100mm 和肝内肿瘤数量≤2 的患者 MST 和 3 年 OS 率分别为 39.0 个月和 51.9%。

结论

对于合并≥3 个肝内肿瘤的 HCC 患者,即使所有肝内肿瘤均可通过肝切除术消除,也不建议行肝切除术。对于最大肿瘤直径<100mm 且肝内肿瘤数量≤2 的 HCC 患者,无论是否存在血管侵犯,积极手术可能是合理的。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验